Background: To date, numerous nucleic acid species have been detected in the systemic circulation including microRNAs (miRNAs); however, their functional role in this compartment remains unclear.
I
t is now widely accepted that microRNAs (miRNAs) are present in the circulation; however, their precise function in this compartment is not completely understood (1) (2) (3) . miR-375 is an abundant miRNA that has been identified in several tissues, including pancreatic islets, the pituitary, adrenal glands, and the gastrointestinal tract (4) . Whereas miR-375 has been established as a regulator of pancreatic b-cell function, its expression profile beyond this one cell type suggests a prominent role in other metabolic processes (5) (6) (7) . Previous reports have identified miR-375 in the blood, indicating that endocrine cells may contribute to its presence in circulation (1) . As studies also now show alterations in systemic levels of miRNAs during disease states, it is still unclear how the kinetics of the miRNAs in circulation reflect changes in metabolism and physiology (8) . Whether the miRNAs are actively released in response to changes in systemic glucose or other factors present in blood or whether they are constitutively released has also not been described.
In response to dietary intake, several hormones, including insulin and the incretins glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), are released into the blood to facilitate several physiological processes and ultimately to lower blood glucose levels by promoting insulin release (9) . GLP-1 is released by the intestinal endocrine L-cells and performs an array of functions in addition to its direct action on the b-cell. GLP-1 acts to slow gastric emptying while indirectly inhibiting glucagon secretion via the release of somatostatin. Meanwhile, GIP present in the K-cells of the small intestine will facilitate energy storage via direct action on adipose tissue and promote bone formation by increasing osteoblast proliferation (9) . Studies primarily in rodent models have begun to explore the role of GLP-1 and GIP in other tissues, including the brain, and together, these observations highlight the complex nature of incretin action in the context of energy homeostasis.
In this study, we sought to determine whether miRNAs are released into the systemic circulation following a glucose challenge in human subjects and whether the presence of specific miRNAs coincides with established factors regulating glucose homeostasis. To date, extensive miRNA profiling has been performed on human tissues including blood. In this study, we show the systemic level of miR-375 is increased following oral ingestion of glucose, implicating a role for the gut in the release of this small RNA into circulation. We also observe that miR-375 is the most highly abundant and enriched miRNA in Sox9-High cells of the intestine and robustly expressed and enriched in Sox9-Low cells, suggesting that the enteroendocrine cell population, and possibly the proliferating cells of the intestinal crypt, may contribute to systemic levels of this miRNA.
Materials and Methods

Human patient samples
As previously reported, approval was obtained from the Danish Data Protection Agency (2007-58-0010) and the Ethics Committee of the Central Denmark Region (1-16-02-377-13), and informed consent was obtained from all patients for being included in the study (10) . Twelve healthy Caucasian males, aged 20 to 50 years, participated in the study, which was registered at ClinicalTrials.gov (NCT02213276). During the oral glucose tolerance test (OGTT) and IGII experiments, blood samples were collected at 0, 15, 30, 60, 120, and 180 minutes from receiving the glucose load, which lasted 5 minutes. For the 3-hour fasting control experiment, blood samples were collected after 0, 1, 2, and 3 hours. Blood samples for plasma analysis of insulin, GIP, GLP-1, and GLP-2 were prepared and quantified at the Department of Clinical Biochemistry at Aarhus University Hospital accredited in accordance with ISO15189 (10). After collection, blood samples were centrifuged at 2000g for 10 minutes and then stored at 280°C until analysis. Plasma insulin was measured by ELISA (K6219; DakoCytomation). All samples were extracted in a final concentration of 70% ethanol before GIP and GLP-1 measurements and 75% before GLP-2 measurements. Total GIP was measured using a radioimmunoassay with a C-terminally directed antibody (antiserum 80867), which reacts fully with intact GIP and N-terminally truncated forms (11) . The standard was human GIP (H-5645; Bachem), and the tracer was 125 I-labeled human GIP (Nex402; PerkinElmer). Total GLP-1 was measured using a radioimmunoassay with an antibody (antiserum 89390) specific for the C-terminus of the GLP-1 molecule and reacting equally with intact GLP-1 and the primary (N-terminally truncated) metabolite (12) . Intact GLP-2 was measured using a radioimmunoassay as originally described (13) . The antiserum (code number 92160) is directed against the N-terminus of GLP-2 and therefore measures only fully processed GLP-2 of intestinal origin. For standards, we used recombinant human GLP-2, and the tracer was 125 I-labeled rat GLP-2 with an Asp33 → Tyr33 substitution. Sensitivity for all of the radioimmunoassays was ,5 pmol/L and intraassay coefficient of variation ,10%.
Gene expression analysis
Total RNA was isolated from plasma using TRIzol LS (Invitrogen) with glycogen as a carrier. miRNAs were quantified by TaqMan Assays using the TaqMan MicroRNA Reverse Transcription Kit and miRNA-specific primer sets (Thermo Fisher Scientific). Plasma miR-375, miR-148a, and miR-27b levels were normalized to miR-16 expression in each respective sample.
Small RNA-sequencing analysis
Raw miRNA counts were retrieved from Supplemental Table 4 of Kang et al. 2017 (14) . The publically available data were downloaded from Sequence Read Archive FTP site and National Center for Biotechnology Information dbGaP on 8 December 2015, resulting in 823 data sets from human tissue samples from and 395 data sets originating from serum and cerebrospinal fluid (CSF). The precise details of the analysis can be retrieved from the Material and Methods section of Kang et al. 2017 (14) .
Tissue samples were normalized to estimated number of miRNA molecules per cell, and we assumed the total amount of miRNA per cell to be ;100,000 (15) . Counts for individual miRNA were divided by the sum of all miRNA reads in the sample and multiplied with the assumed total miRNA abundance. The same normalization was applied to body fluid samples but, as the total abundance of miRNA in those fluids is unknown, the values do not represent copies per cell and are indicated as arbitrary units. In total, 1787 miRNA were detected and analyzed; independent sample sizes were blood cells (n = 197), liver cells (n = 93), brain cells (n = 102), serum samples (n = 212), exosome samples (n = 37), and CSF (n = 180). In summary, the number of times a given miRNA is detected in sequencing depends on its abundance and the overall sequencing depth (16) .
For small RNA-sequencing from gut tissue of Sox9-EGFP mice, intestinal epithelial cell isolation and fluorescenceactivated cell sorting was performed with the University of North Carolina Flow Cytometry Core Facility as described previously (17) . RNA was isolated from sorted subpopulations using the Total RNA Purification Kit (Norgen Biotek), and small RNA libraries were prepared with a range of ;60 ng to ;850 ng of total RNA using the CleanTag Small RNA Ligation Kit (TriLink Biotechnologies) at the sequencing facility at the University of Texas Health Sciences Center at San Antonio. Libraries were sequenced on the HiSeq2500 platform (Illumina), yielding an average of ;40 million total reads per sample. Raw sequencing data and miRNA quantification tables for all samples can be accessed through the National Center for Biotechnology Information Gene Expression Omnibus accession number GSE102687.
Animal studies
All animal studies were approved by the Institutional Animal Care and Use Committee at the University of North Carolina, where the mouse experiments were performed. Chow-fed male Sox9-EGFP mice were housed in cages with one-quarter-inch Bed-o'Cobs laboratory animal bedding (The Andersons Inc.). At 24 to 28 weeks of age, the mice were anesthetized using isoflurane and then euthanized by cervical dislocation.
Statistical analysis
Comparisons between data sets with two groups were evaluated using an unpaired Student t test. Repeated-measures analysis of variance was performed using Prism Software 6.07 (GraphPad) to compare levels of miR-375, glucose, insulin, and gastrointestinal hormones among OGTT, isoglycemic intravenous glucose infusion (IIGI), and the 3-hour fasting control (Supplemental Table 1 ). Post hoc statistics were performed using Sidak multiple-comparison test. A P value of #0.05 was considered statistically significant.
Results
Quantification of miR-375 in human blood
Surveying miRNA abundances in .800 human samples from six different tissues and body fluids, we observed high abundances of miR-16 in all analyzed tissues, including blood cells, liver, brain, serum, exosome, and CSF samples (Fig. 1a and 1b) . In contrast, miR-375 was only abundant in serum, exosomes, liver, and CSF, whereas it was moderately expressed in the brain and virtually absent in blood cells. This lack of expression in blood cells suggests that miR-375 may be exported into the bloodstream by adjoining tissues. In contrast, miR-124 was found to be only moderately expressed in the brain and was at low levels in all other analyzed tissues (Fig. 1b) . This further underlines the differential tissue expression pattern and function of miRNAs.
Systemic miR-375 increases during OGTT
In light of its abundance in circulation, we quantified systemic miR-375 levels in the plasma of healthy human subjects in response to either an OGTT or IIGI. Blood glucose levels were comparable between the OGTT and IIGI experiments (Fig. 2a) . The plasma miR-375 level significantly increased during the OGTT, when it reached a maximum after 60 and 120 minutes (;4.8-and ;5.3-fold increase, respectively) and returned to baseline level after 180 minutes. In contrast, during the IIGI, expression of this miRNA remained indistinguishable from steady-state levels ( Fig. 2a; Supplemental Fig. 1a and Supplemental Table 1 ). The oral glucose administration resulted in a pronounced increase in circulating gut hormones GIP, GLP-1, GLP-2 (at time 30 minutes, ;3.9-, ;2.2-, and ;3.5-fold increase, respectively) as well as plasma insulin (;8.5-fold) as recently published (Fig. 2b-2f) (10) . During the intravenous glucose infusion, plasma levels of GIP, GLP-1, and GLP-2 remained at baseline levels, whereas insulin showed only a small increase (Fig. 2c-2f) . Together, these results indicate the temporal rise in miR-375 correlates with increased levels of the gut hormones, and this is further supported with both area under the curve calculations and analyzing miR-375 levels using analysis of covariance, as plotted in relation to GIP or GLP-1 (Supplemental Fig. 1b-1e) . Meanwhile, we also addressed the expression of two additional miRNAs abundant in human serum, miR-148a, and -27b, and observed no changes in systemic levels during the OGTT or IIGI (Suppementary Fig. 2a and 2b) (14) .
miR-375 is enriched in enteroendocrine cells
We next performed small RNA-sequencing on intestinal epithelial subpopulations isolated from 24-to 28-week-old male Sox9-EGFP reporter mice to identify cell types enriched for miR-375 (Fig. 3) (18, 19) . As described previously, fluorescence-activated cell sorting resulted in four independent cell populations: the Sox9 High group is enriched for enteroendocrine cells and reserve/ quiescent intestinal stem cells (Fig. 3a) , Sox9
Low is enriched for actively cycling intestinal stem cells (Fig. 3b) 
, Sox9
Sublow is enriched for transit amplifying cells (Fig. 3c) , and Sox9
Neg is enriched for enterocytes (Fig. 3d) (17) . Together, these results show that miR-375 is the most highly 
Discussion
Our knowledge is incomplete concerning the dynamics and function of the majority of circulating factors in human blood. It has long been known that administration of glucose orally vs intravenously differentially affects the release of insulin due to the role of the incretins in islet cell function; however, the full extent to the interplay of these endocrine factors in the context of glucose and energy metabolism remains to be determined (20, 21) . In the current study, we observed the presence of miRNA sequences known to be enriched in tissues central to the regulation of glucose and energy homeostasis including miR-375. Interestingly, higher levels of miR-375 were observed in the plasma of human subjects following an oral glucose challenge in contrast to an intravenous glucose infusion. Levels of miR-375 peaked 30 minutes after the peaks of insulin and incretins, establishing that systemic increase of miR-375 is temporally associated the release of these hormones. The differential response of miR-375 in blood may yet identify an additional physiologic function of the gut or its secreted incretin hormones. Consistent with previous observations, both methods of glucose administration achieved similar blood glucose levels, whereas the insulin secretory response was diminished during the IIGI (22, 23) . The robust increase in plasma insulin levels quantified during the OGTT coincided with a concomitant increase in plasma GLP-1, GLP-2, and GIP. Hence, these results present correlative evidence that the gut may play either a direct or an indirect role in the regulation of the circulating levels of miR-375 in response to oral glucose. It is also unclear whether our results are related to previous studies measuring miR-375 in blood after pharmacological destruction of b-cell mass; previous studies have reported an alteration in the cellular distribution within the gastrointestinal tract after administration of streptozotocin to mice (24) (25) (26) . Latreille et al. (25) reported that the pancreatic b-cell, the cell type expressing the highest levels of miR-375, contributes to ;1% of the systemic miR-375 levels, indicating that the amount of miRNAs released by the b-cell is either https://academic.oup.com/jcemnegligible in comparison with other tissues or they are rapidly taken up or degraded once in circulation. It is also possible that several endocrine cell types release miR-375 in response to incretin signaling in line with their role as paracrine effectors and insulin secretagogues. Our observations in this study showing a rise in miR-375 levels in blood following the oral intake of glucose suggests several possibilities regarding the role of the gut with regard to the presence miRNAs in circulation. First, circulating levels of this miRNA may either originate from the gut or respond to signaling molecules released by this tissue. Our profiling results from sorted cells of the gut confirm miR-375 to be highly abundant in subpopulations enriched for both enteroendocrine cells and intestinal stem cells (and also present albeit at lower levels in transit-amplifying cells and enterocytes) (27) . In light of the heterogeneity of L-cells, another possibility is that L-cells of the upper gut act primarily in nutrient sensing, whereas in the lower gut, these cells contribute to the release of miR-375 (28) . The highest levels of miR-375 were measured between 30 and 120 minutes postadministration; therefore, the presence of this miRNA in the secretory granules storing either insulin or GLP-1 is unlikely. It is unclear how many additional miRNAs the differential impact of oral glucose vs intravenous on systemic levels will be shown to affect, as abundant sequences such as miR-148a and miR-27b were observed not altered.
A recent study by Thomou et al. (29) has shown evidence that circulating miRNAs are derived from adipose tissue and able to target genes of the liver. Using a tissuespecific knockout of the miRNA-processing enzyme Dicer, they observed a decrease in circulating miRNAs present in exosomes and that overexpression of miR-99b was able to suppress activity of a reporter construct containing the 3 0 untranslated region of the gene Fgf21, a circulating factor expressed by the liver and other tissues (29) . miR-375 is also detected in liver, and whereas expression of miR-375 in this tissue is several magnitudes lower than the levels measured in the pancreatic islet, miR-122 is detected in blood, suggesting the hepatocyte is also a site of miRNA export (6, 30, 31) . However, it would be prudent for future investigations to determine whether the measured amounts of miR-375 are endogenous expression from hepatocytes. Given the volume of blood transported throughout the liver, it is likely a considerable fraction of miR-375 expression quantified in this tissue is derived from its presence in the systemic circulation. Therefore, the functional relevance of miR-375 in the liver at steady-state conditions is unclear at this time. Given the dozens of other more abundant miRNA sequences present, most notably miR-122, the function of low-expressed miRNAs is not known based on the absence of strong evidence showing target regulation in vivo. Although dysregulation of miR-375 target genes in the liver cannot be ruled out, none of the targets of this miRNA that were experimentally validated using knockout tissues have been studied in the context of glucose or lipid metabolism in the liver (4) . The mild hyperglycemia observed in miR-375 knockout mice appears to result from increased glucagon levels stemming from increased a-cell mass in the islet (4) .
In summary, our observations on miR-375 in circulation continue to reflect the exceedingly complex and dynamic state of human blood following glucose uptake. In light of the temporal relationship between miR-375 and incretin hormones, future studies should explore the physiological relevance of miRNA in circulation and whether functional overlap exists between noncoding RNA and signaling hormones.
